Bill brings state into national efforts at prescription drug monitoring programs (PDMPs), and adds requirements to pharmacists and distributors
With complete unanimity in both its upper and lower houses, the Florida legislature passed a bill, HB 7095; it now awaits Governor Rick Scott’s signature and then will go into effect on July 1. Florida, which its own legislators have called the “pill mill capital of world,” has been plagued by marginally legal pain management clinics that routinely dispense high volumes of addictive pain meds (including opioids, benzodiazeprines and barbiturates). The pill mills attracted a high volume of patients from out of state, who would return to their home states and sell the drugs illegally. In 2009, state law enforcement reported that nine people a day were dying from pain med overdoses.
All this did not prevent Gov. Scott and some legislators from attempting to derail the state’s efforts to organize a prescription drug monitoring program (PDMP), similar to that in effect in 30 other states, to prevent patients from doctor- and pharmacy-shopping to load up on prescriptions. Scott expressed a concern that patient privacy was at risk, and that the state couldn’t afford to fund the PDMP. The new bill both overcomes those objections, and seems to go as far as legislation can in restricting pain-med prescribing to pharmacies associated with hospitals, or to large, publicly held pharmacy chains and care facilities.
The bill mandates certifications for physicians and pharmacists; increases penalties for violations; and establishes the framework by which a PDMP will operate and how it will divulge prescribing information. Pharmacists are obligated to report any suspect attempted acquisition of pain meds. Wholesalers servicing the state (both local and out-of-state) are obliged to maintain “suspicious ordering” system reviews and report trend data to the state, and all parties are pressed to make use of DEA’s Constrolled Substances Ordering System (CSOS). Data are to be reported to the PDMP within seven days.
Florida’s legislation meshes neatly with the federal call to action, “Epidemic,” that was published in April. That multi-agency effort hopes to both propose new legislation, and to coordinate agencies activities.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.